You are here

Home » About PI

Immunoglobulin (Ig) Replacement Therapy

Ig replacement therapy is both lifesaving and often lifelong, and is one of the most important and successful therapies for people with PI that affect antibody production.
Learn More

Immunoglobulin Product Guide

IDF's downloadable booklet showing the characteristics of immunoglobulin products used to treat primary immunodeficiencies licensed for use in the United States.
Learn More

Manufacturers & Assistance Programs

Learn more about the manufacturers who make products for people with PI, as well as reimbursement assistance programs on their websites.
Learn More

Addressing the Ongoing Plasma / Ig Shortage

Since late 2018, the Immune Deficiency Foundation (IDF) has been tracking a troubling shortage of plasma-based immunoglobulin (Ig) products, which are lifesaving, lifelong treatments for people with primary immunodeficiencies (PI), specifically those who are antibody deficient. We continue to monitor the situation day-to-day and week-to-week and offer guidance and input where we can to make a difference.

Learn More

Clinical Trials

Clinical trials are necessary to develop safe and effective products with limited side effects while providing the most therapeutic benefit.
Learn More

Gene Therapy

Gene therapy is an experimental treatment that has been used to treat people with severe forms of PI, who do not have a matched sibling donor.
Learn More

Hematopoietic Stem Cell Transplantation

When PI is likely to cause significant harm or death to someone, Hematopoietic Stem Cell Transplantation (HSCT) may be the best treatment option.
Learn More

Treatment Info for Insurers & Payers

With appropriate treatment, many people with primary immunodeficiencies (PI) can live healthy productive lives and payers save by avoiding the costs of expensive resources including hospital care, tests and procedures. In order to best manage therapies, payers need resources and education surrounding PI treatment.

IDF seeks to educate and work collaboratively with payers to ensure that patients receive appropriate treatment and have access to the therapies they require. Click below to view a collection of resources and educational information surrounding the treatment of primary immunodeficiencies.

Learn More